Literature DB >> 21324305

Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor.

Øystein L Holla1, Jon K Laerdahl, Thea Bismo Strøm, Kristian Tveten, Jamie Cameron, Knut Erik Berge, Trond P Leren.   

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low density lipoprotein receptor (LDLR) at the cell surface and mediates intracellular degradation of the LDLR. The amino-terminus of mature PCSK9, residues 31-53 of the prodomain, has an inhibitory effect on this function of PCSK9, but the underlying mechanism is not fully understood. In this study, we have identified two highly conserved negatively charged segments (residues 32-40 and 48-50, respectively) within this part of the prodomain and performed deletions and substitutions to study their importance for degradation of the LDLRs. Deletion of the acidic residues of the longest negatively charged segment increased PCSK9's ability to degrade the LDLR by 31%, whereas a modest 8% increase was observed when these residues were mutated to uncharged amino acids. Thus, both the length and the charge of this part of the prodomain were important for its inhibitory effect. Deletion of the residues of the shorter second negatively charged segment only increased PCSK9's activity by 8%. Substitution of the amino acids of both charged segments to uncharged residues increased PCSK9's activity by 36%. These findings indicate that the inhibitory effect of residues 31-53 of the prodomain is due to the negative charge of this segment. The underlying mechanism could involve the binding of this peptide segment to positively charged structures which are important for PCSK9's activity. One possible candidate could be the histidine-rich C-terminal domain of PCSK9.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21324305     DOI: 10.1016/j.bbrc.2011.02.023

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

Review 1.  The PCSK9 decade.

Authors:  Gilles Lambert; Barbara Sjouke; Benjamin Choque; John J P Kastelein; G Kees Hovingh
Journal:  J Lipid Res       Date:  2012-07-17       Impact factor: 5.922

2.  Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein.

Authors:  Fen Du; Yvonne Hui; Michelle Zhang; MacRae F Linton; Sergio Fazio; Daping Fan
Journal:  J Biol Chem       Date:  2011-10-25       Impact factor: 5.157

3.  Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors.

Authors:  Øystein L Holla; Jamie Cameron; Kristian Tveten; Thea Bismo Strøm; Knut Erik Berge; Jon K Laerdahl; Trond P Leren
Journal:  J Lipid Res       Date:  2011-07-19       Impact factor: 5.922

4.  The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway.

Authors:  Yascara Grisel Luna Saavedra; Robert Day; Nabil G Seidah
Journal:  J Biol Chem       Date:  2012-10-26       Impact factor: 5.157

5.  APOM and high-density lipoprotein cholesterol are associated with lung function and per cent emphysema.

Authors:  Kristin M Burkart; Ani Manichaikul; Jemma B Wilk; Firas S Ahmed; Gregory L Burke; Paul Enright; Nadia N Hansel; Demondes Haynes; Susan R Heckbert; Eric A Hoffman; Joel D Kaufman; Jun Kurai; Laura Loehr; Stephanie J London; Yang Meng; George T O'Connor; Elizabeth Oelsner; Marcy Petrini; Tess D Pottinger; Charles A Powell; Susan Redline; Jerome I Rotter; Lewis J Smith; María Soler Artigas; Martin D Tobin; Michael Y Tsai; Karol Watson; Wendy White; Taylor R Young; Stephen S Rich; R Graham Barr
Journal:  Eur Respir J       Date:  2013-07-30       Impact factor: 16.671

Review 6.  The Multifaceted Biology of PCSK9.

Authors:  Nabil G Seidah; Annik Prat
Journal:  Endocr Rev       Date:  2022-05-12       Impact factor: 25.261

Review 7.  The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.

Authors:  Steve Poirier; Gaétan Mayer
Journal:  Drug Des Devel Ther       Date:  2013-10-04       Impact factor: 4.162

Review 8.  PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.

Authors:  Thomas A Lagace
Journal:  Curr Opin Lipidol       Date:  2014-10       Impact factor: 4.776

9.  Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations.

Authors:  Janice Mayne; Teik Chye Ooi; Angela Raymond; Marion Cousins; Lise Bernier; Thilina Dewpura; Francine Sirois; Majambu Mbikay; Jean Davignon; Michel Chrétien
Journal:  Lipids Health Dis       Date:  2013-05-10       Impact factor: 3.876

10.  Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.

Authors:  Tanja Kosenko; Mia Golder; Geoffrey Leblond; Willy Weng; Thomas A Lagace
Journal:  J Biol Chem       Date:  2013-02-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.